Interim data demonstrates 12-month survival rate of 87% with PDS 0101 in combination with Keytruda for head and neck cancer patients.-PDS Biotechnology Corporation.
PDS Biotechnology Corporation, announced promising interim data from the VERSATILE-002 (NCT04260126) Phase II clinical trial investigating PDS 0101 in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer
The results will be featured in a poster presentation and in a head and neck cancer expert panel discussion at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago.
The presentation, titled “Safety and Efficacy of Immune Checkpoint Inhibitor (ICI) Naïve Cohort from Study of PDS0101 and Pembrolizumab in HPV16-positive Head and Neck Squamous Cell Carcinoma (HNSCC)” (Abstract #6012), concluded that the combination was well tolerated, and the results justify a global confirmatory randomized, controlled study, VERSATILE-003, which PDS Biotech is planning to initiate this year. The study’s 48 ICI naïve participants, 94% of whom were male with a median age of 62.5, received at least one cycle of the combination arm, 56.3% received four doses, and 22.9% received five doses.
In measuring the efficacy of PDS 0101 in combination with Keytruda the abstract highlights the following interim data: i. Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone. ii. Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels. iii. A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34) iv. Confirmed and unconfirmed objective response rate was 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported at ASCO 2022 (7/17 patients). To date these responses have been confirmed in nine of the 34 patients (26.5%), including one complete response. v. 15/34 patients (44.1%) had stable disease. vi. 9/34 patients (26.5%) had progressive disease. vii.4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.
PDS 0101 in combination with Keytruda is currently in Phase III trials for Head and Neck Cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins